Read by QxMD icon Read

carcinoma of bladder

Hiroshi Juri, Mitsuhiro Koyama, Haruhito Azuma, Yoshifumi Narumi
PURPOSE: The purpose of the study was to retrospectively determine whether there are metastases to the chest in patients with primary non-muscle-invasive urothelial carcinoma in the bladder on the follow-up computed tomography (CT). METHODS: We analyzed 328 patients with follow-up chest CT for urothelial carcinoma of the bladder diagnosed between January 2004 and September 2013. We divided patients into four groups: Ta (n = 74), T1 (n = 78), carcinoma in situ (CIS, n = 25), and ≥ T2 (n = 151)...
August 16, 2018: International Urology and Nephrology
Laila Al-Eryani, Samantha F Jenkins, Vanessa A States, Jianmin Pan, Janine C Malone, Shesh N Rai, Susan Galandiuk, Ashok K Giri, J Christopher States
Arsenic, a naturally occurring element, contaminates the drinking water of over 200 million people globally. Chronic arsenic exposure causes multiple cancers including those originating from skin, lung and bladder, and is associated with liver, kidney, and prostate cancers. Skin is the primary target organ for arsenic toxicity; chronic toxicity initially manifests as non-malignant hyperkeratoses (HK) and subsequently advances to malignant lesions, including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)...
2018: PloS One
Liliana Vartolomei, Matteo Ferro, Vincenzo Mirone, Shahrokh F Shariat, Mihai Dorin Vartolomei
Background: Depression affects more than 300 million people of all ages worldwide. In patients with cancer the reported prevalence is up to 24%. Objective: To systematically review the literature to report the prevalence of depression and anxiety among patients with bladder cancer (BC). Methods: Web of Science, MEDLINE/PubMed, and The Cochrane Library were searched between January and March 2018 using the terms "bladder carcinoma OR bladder cancer AND depression OR anxiety"...
July 30, 2018: Bladder Cancer
Elizabeth Germino, Benjamin W Fischer-Valuck, Soumon Rudra, Yuan James Rao, Jessika Contreras, Christopher Abraham, Jeff Michalski, Hiram Gay
Purpose: To determine whether total radiation dose affects survival outcomes for patients with small cell carcinoma of the bladder (SCCB). Methods: We queried the National Cancer Database (NCDB) for patients with limited stage SCCB undergoing multimodality treatment and retrospectively analyzed survival outcomes according to total radiation dose received. Results: Patients aged 41-79 receiving a total radiation dose of 54 Gy or greater had a significant improvement in overall survival compared to those receiving less than 54 Gy, with a median overall survival of 58...
July 30, 2018: Bladder Cancer
Cedric A D'Hue, Deepika Dhawan, Tyler Peat, José Ramos-Vara, Alan Jarmusch, Deborah W Knapp, R Graham Cooks
Background: In early work ambient ionization mass spectrometry (MS) revealed lipid patterns distinguishing muscle invasive bladder cancer (invasive urothelial carcinoma, InvUC) from normal urothelium. A new ambient ionization MS approach, touch spray MS (TS-MS) can rapidly generate mass spectra in real time, potentially in a point-of-care setting. A tissue sample removed from a patient is touched by a probe, and mass spectra generated within seconds. Objective: To validate TS-MS methods using specimens from naturally-occurring InvUC in dogs where the cancer closely mimics the human condition, and to demonstrate proof-of-concept that TS-MS can elucidate lipid patterns distinguishing InvUC from normal urothelium...
July 30, 2018: Bladder Cancer
Dora Huang, Surena F Matin, Nathan Lawrentschuk, Morgan Roupret
Background: Lynch syndrome is an autosomal dominant disorder that predisposes individuals affected to certain malignancies. Colon and endometrial cancers are the malignancies most highly associated with Lynch syndrome. However, growing body of evidence links Lynch syndrome to urological cancers. Objective: This review aims to clarify the type of urological malignancies that fall under the Lynch-associated cancer spectrum. Methods: Using PRISMA guidelines, a systematic search between January 1990 to February 2018, was conducted using the MEDLINE database with the application of the following MESH terms: colorectal neoplasms, hereditary nonpolyposis; DNA mismatch repair; urologic neoplasms; kidney pelvis; ureteral neoplasms; urinary bladder; carcinoma, transitional cell; prostatic neoplasms; testicular neoplasms...
July 30, 2018: Bladder Cancer
Panagiotis J Vlachostergios, Christopher D Jakubowski, Muhammad J Niaz, Aileen Lee, Charlene Thomas, Amy L Hackett, Priyanka Patel, Naureen Rashid, Scott T Tagawa
Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC...
July 30, 2018: Bladder Cancer
Shengping Zhang, Jiarong Cai, Wenjun Xie, Hui Luo, Fei Yang
MicroRNA (miR)-202 has been reported to be involved in the regulation of human cancer progression including bladder cancer, non-small cell lung cancer, pancreatic cancer and esophageal squamous cell carcinoma. However, the function of miR-202 in prostate cancer remains largely unknown. The present study demonstrated that miR-202 was downregulated in human prostate cancer tissues and cell lines. And overexpression of miR-202 significantly inhibited the proliferation, migration and invasion of prostate cancer cells, but induced cell apoptosis...
August 2018: Experimental and Therapeutic Medicine
Leonardo L Monteiro, J Alfred Witjes, Piyush K Agarwal, Christopher B Anderson, Trinity J Bivalacqua, Bernard H Bochner, Joost L Boormans, Sam S Chang, Jose L Domínguez-Escrig, James M McKiernan, Colin Dinney, Guilherme Godoy, Girish S Kulkarni, Paramananthan Mariappan, Michael A O'Donnell, Cyrill A Rentsch, Jay B Shah, Eduardo Solsona, Robert S Svatek, Antoine G van der Heijden, F Johannes P van Valenberg, Wassim Kassouf
PURPOSE: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC). METHODS: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma in situ [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments...
August 14, 2018: World Journal of Urology
Carolyn Hurst, Jonathan Rosenberg, Margaret Knowles
Bladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes. Recent genomic and transcriptomic data have significantly improved tumor sub-classification and prognostication for both patient groups and are informing improved approaches to treatment of muscle-invasive disease. To view this SnapShot, open or download the PDF...
August 13, 2018: Cancer Cell
S Theurer, U Siebolts, K Lorenz, H Dralle, K W Schmid
Ectopic thyroid tissue results from developmental defects of the early stages of thyroid embryogenesis, in which the median thyroid anlage descends from the floor of the mouth to its final pre-tracheal position. The most common sites of ectopic thyroid tissue are accordingly in the area of the floor of the mouth and in the course of the thyroglossal duct. Rare localizations are intrathoracic (mediastinal, cardiac, pulmonary) and sub-diaphragmatic (including the adrenals, liver, gall bladder, and gastrointestinal tract)...
August 13, 2018: Der Pathologe
Shagun Misra, Punita Lal, Saibish Kumar Ep, Neeraj Rastogi, Anu Tiwari, Shalini Singh, K J Maria Das, Shaleen Kumar
BACKGROUND: A randomised trial was carried out comparing chemo-radiation (CTRT) vs. radiotherapy (RT) in patients of carcinoma cervix and showed similar rates of pelvic disease control, disease free survival and overall survival. Late toxicity is presented. METHODS: Between December 2000 and July 2006, 180 patients of carcinoma cervix were randomly assigned to RT + weekly cisplatin (n = 94) or RT alone (n = 86). Late toxicity was prospectively scored using RTOG criteria in 156 evaluable patients, 79 and 77 respectively and is presented as crude incidence for rectum, bladder, small intestine, vagina, skin and bone and also as actuarial incidence for rectum and bladder...
2018: Cancer Treatment and Research Communications
Francesca Bravi, Maria-Eleni Spei, Jerry Polesel, Matteo Di Maso, Maurizio Montella, Monica Ferraroni, Diego Serraino, Massimo Libra, Eva Negri, Carlo La Vecchia, Federica Turati
Previous studies have reported that Mediterranean diet is inversely related to the risk of several neoplasms; however, limited epidemiological data are available for bladder cancer. Thus, we examined the association between Mediterranean diet and this neoplasm in an Italian multicentric case-control study consisting of 690 bladder cancer cases and 665 controls. We assessed the adherence to the Mediterranean diet via a Mediterranean Diet Score (MDS), which represents the major characteristics of the Mediterranean diet and ranges from 0 to 9 (from minimal to maximal adherence, respectively)...
August 10, 2018: Nutrients
Andreea Nissenkorn, Tomer Erlich, Dorit E Zilberman, Ifat Sarouk, Alexander Krauthammer, Noam D Kitrey, Gali Heimer, Bruria BenZeev, Yoram Mor
BACKGROUND: Ataxia telangiectasia (AT) is a neurodegenerative cerebellar disorder, caused by mutations in the ATM gene, involved in DNA repair. Radiosensitivity, progressive ataxia, immune deficiency and malignancies, are well known symptoms, but urological manifestations are scarcely described. OBJECTIVE: To characterize urologic manifestations in a large cohort of AT patients. METHODS: Retrospective cross-sectional chart study comprising 52 AT patients followed at a National AT Center...
July 26, 2018: European Journal of Paediatric Neurology: EJPN
S Manekeller, J C Kalff
BACKGROUND: Although the treatment and diagnostic regimens of gall bladder carcinoma and extrahepatic bile duct cancer have improved over the past years, the outcome and overall survival as prognostic values still remain poor. Early tumor stages of gall bladder carcinoma are the only exception. OBJECTIVE: This article focuses on the latest surgical therapy approaches including neoadjuvant, adjuvant and palliative therapy regimens. RESULTS: Neoadjuvant treatment concepts have so far been insufficiently evaluated and can therefore only be recommended within the framework of studies...
August 9, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
David P Sellman, Leslie Peard, Greg Simpson, Katrina Lancaster, Sravan Kavuri, Martha Terris, Rabbi Madi
The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%-28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma...
July 2018: Urology Annals
Santosh Kumar, Sriharsha Ajjur Shankaregowda, Abhishek Chandna
Inflammatory pseudotumor is a rare benign condition of unknown cause. A 19-year-old female presented with gross hematuria and storage symptoms to the emergency. Contrast-enhanced computed tomography scan revealed a mass of 5 cm × 6 cm involving the dome and anterior wall of the bladder. Urachal carcinoma was kept as a possibility and transurethral biopsy of the aforementioned lesion was performed. The histopathology revealed inflammatory myofibroblastic tumor (IMT) of the bladder. A laparoscopic partial cystectomy was undertaken with adequate resection margins and the histopathology of the lesion confirmed IMT...
July 2018: Urology Annals
Deepika Dhawan, Noah M Hahn, José A Ramos-Vara, Deborah W Knapp
There is growing evidence that molecular subtypes (e.g. luminal and basal subtypes) affect the prognosis and treatment response in patients with muscle invasive urinary bladder cancer (invasive urothelial carcinoma, iUC). Modeling these subtypes in pre-clinical animal studies is essential, but it is challenging to produce these subtypes, along with other critical host and tumor features, in experimentally-induced animal models. This study was conducted to determine if luminal and basal molecular subtypes are present in naturally-occurring canine iUC, a cancer that mimics the human condition in other key aspects...
August 8, 2018: PLoS Genetics
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, Elizabeth Plimack
The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United States Food and Drug Administration (FDA) approved. In cisplatin-ineligible patients, atezolizumab and pembrolizumab are the FDA-approved checkpoint inhibitors. Here we describe the updated clinical efficacy of these checkpoint inhibitors in the treatment of advanced urothelial carcinoma and then suggest how they can be sequenced in the context of available chemotherapeutic options...
2018: Therapeutic Advances in Medical Oncology
Julie E Kim, Dorothy Martinez
No abstract text is available yet for this article.
August 3, 2018: Endocrinología, Diabetes y Nutrición
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"